Failure of adjunctive cytomegalovirus intravenous immune globulin to improve efficacy of ganciclovir in patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis: a phase 1 study.

Abstract

Six men with acquired immunodeficiency syndrome (AIDS) and cytomegalovirus (CMV) retinitis, treated with combined ganciclovir induction therapy and hyperimmune globulin (CMV-IGIV) for 10 days followed by CMV-IGIV alone, had a median time to retinitis progression shorter (7 days) than had eight historical controls given ganciclovir maintenance therapy (54 days; P = 0.06) and similar to that in eight controls given ganciclovir for 10 days only (19 days; P = 0.97). CMV-IGIV, which also failed to inhibit CMV replication in blood and urine, did not appear to add markedly to the efficacy of ganciclovir in acquired immunodeficiency syndrome-associated CMV retinitis.

• Authors: M A Jacobson, J J O'Donnell, R Rousell, B Dionian, J Mills 5th
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 34 Issue 1 Pg. 176-8 (Jan 1990) ISSN: 0066-4804 [Print] United States
• PMID: 2158273 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Globulins
• Ganciclovir

Topics

• Acquired Immunodeficiency Syndrome (complications, therapy)
• Adult
• Cytomegalovirus (immunology)
• Cytomegalovirus Infections (complications, therapy)
• Ganciclovir (adverse effects, therapeutic use)
• Globulins (adverse effects, immunology)
• Humans
• Male
• Retinitis (complications, therapy)